haloperidol has been researched along with citalopram in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.77) | 18.7374 |
| 1990's | 9 (16.98) | 18.2507 |
| 2000's | 22 (41.51) | 29.6817 |
| 2010's | 17 (32.08) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Sen, S; Sinha, N | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Peters, JU | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bucki, A; Gryboś, A; Głuch-Lutwin, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Więckowski, K | 1 |
| Qin, W; Tian, S; Wold, EA; Xu, Q; Ye, N; Zhen, XC; Zhou, J | 1 |
| Briley, M; Moret, C | 1 |
| Maj, J; Rogóz, Z; Skuza, G; Sowińska, H | 1 |
| Maj, J; Rogóz, Z; Skuza, G | 1 |
| Bijak, M; Smiałowski, A | 1 |
| Gerlach, J; Korsgaard, S; Laursen, AL; Noring, U; Povlsen, UJ | 1 |
| Buckland, PR; McGuffin, P; Oretti, RG; Spurlock, G | 1 |
| Fischer-Colbrie, R; Kapeller, I; Kroesen, S; Mahata, M; Mahata, SK; Marksteiner, J; Saria, A; Winkler, H | 1 |
| Earley, B; Faherty, CJ; Leonard, BE | 1 |
| Evenden, JL | 1 |
| Ishikane, T | 1 |
| Morelli, M; Pinna, A | 1 |
| Caccia, S; De Deurwaerdère, P; Lucas, G | 1 |
| Bonomo, V; Fogliani, AM | 1 |
| Geyer, MA; Hell, D; Liechti, ME; Vollenweider, FX | 1 |
| Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Wilson, AA | 1 |
| De Deurwaerdère, P; Moison, D; Porras, G; Spampinato, U | 1 |
| Arnt, J; Bang-Andersen, B; Brennum, LT; Christoffersen, CT; Di Matteo, V; Didriksen, M; Esposito, E; Hertel, P; Larsen, AK; Marcus, MM; Pouzet, B; Ramirez, T; Svensson, TH; Søby, KK | 1 |
| Han, JH; Hong, SC; Ihn, YK; Jeong, JH; Lee, SP; Shin, YK | 1 |
| de Bartolomeis, A; Dell'aversano, C; Iasevoli, F; Tomasetti, C | 1 |
| Ozcan, O; Selimoğlu, MA | 1 |
| Rabasseda, X | 1 |
| Avissar, S; Golan, M; Schreiber, G | 1 |
| Li, M; Sparkman, NL | 1 |
| Bogossian, H; Brücher, B; Dechering, DG; Eckardt, L; Frommeyer, G; Kaese, S; Kochhäuser, S; Milberg, P; von der Ahe, H | 1 |
| Golebiowska, J; Rygula, R | 1 |
| Balcı, N; Demir, Y; Gürbüz, M; Küfrevioğlu, Öİ; Özaslan, MS | 1 |
| Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN | 1 |
| Bakırdere, S; Chormey, DS; Dalgıç Bozyiğit, G; Fırat Ayyıldız, M; Onkal Engin, G | 1 |
4 review(s) available for haloperidol and citalopram
| Article | Year |
|---|---|
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
Topics: Allosteric Regulation; Clinical Trials as Topic; Humans; Ligands; Nervous System Diseases; Piperidines; Receptors, sigma; Sigma-1 Receptor; Small Molecule Libraries | 2020 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Topics: Academic Medical Centers; Aged; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Citalopram; Dementia; Electroconvulsive Therapy; Haloperidol; Humans; Olanzapine; Psychopharmacology; Risperidone | 2021 |
1 trial(s) available for haloperidol and citalopram
| Article | Year |
|---|---|
Citalopram and haloperidol for psychotic depression.
Topics: Adult; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2000 |
48 other study(ies) available for haloperidol and citalopram
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Topics: Affect; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dementia; Dopamine Agonists; Drug Design; Humans; Indoles; Ligands; Models, Molecular; Pyridines; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists | 2017 |
Effect of antidepressant drugs on monoamine synthesis in brain in vivo.
Topics: Animals; Antidepressive Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Citalopram; Clorgyline; Cyclopropanes; Desipramine; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Haloperidol; Hydrazines; Imipramine; Male; Milnacipran; Norepinephrine; Organ Specificity; Parietal Lobe; Rats; Rats, Wistar; Serotonin; Tyrosine 3-Monooxygenase | 1992 |
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Haloperidol; Imipramine; Male; Mianserin; Motor Activity; Prazosin; Rats; Rats, Inbred Strains; Swimming | 1992 |
Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats.
Topics: Amitriptyline; Animals; Antidepressive Agents; Citalopram; Dizocilpine Maleate; Drug Interactions; Haloperidol; Imipramine; Male; Mianserin; Motor Activity; Prazosin; Rats; Rats, Inbred Strains | 1991 |
The effect of acute and prolonged treatment with citalopram on the action of dopamine and SKF 38393 in rat hippocampal slices.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antidepressive Agents; Appetite Depressants; Benzazepines; Citalopram; Dopamine; Ergolines; Haloperidol; Hippocampus; In Vitro Techniques; Male; Motor Activity; Neurons; Propylamines; Quinpirole; Rats; Rats, Inbred Strains; Sulpiride | 1988 |
Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys.
Topics: Animals; Biperiden; Cebus; Citalopram; Dose-Response Relationship, Drug; Dystonia; Haloperidol; Male; Methysergide; Mianserin; Parasympatholytics; Propylamines; Serotonin Antagonists | 1986 |
Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Base Sequence; Brain Chemistry; Citalopram; Clozapine; Gene Expression Regulation; Haloperidol; Male; Mianserin; Molecular Sequence Data; Nerve Tissue Proteins; Rats; Rats, Wistar; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Schizophrenia; Sulpiride | 1994 |
Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Brain; Chromogranins; Citalopram; Clozapine; Haloperidol; Male; Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tissue Distribution | 1995 |
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Topics: 1-Naphthylamine; Animals; Behavior, Animal; Chlorpromazine; Citalopram; Fluoxetine; Fluvoxamine; Guanidines; Haloperidol; Male; Microinjections; Motor Activity; Paroxetine; Piperidines; Posture; Rats; Rats, Sprague-Dawley; Receptors, sigma; Red Nucleus; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
The pharmacology of impulsive behaviour in rats II: the effects of amphetamine, haloperidol, imipramine, chlordiazepoxide and other drugs on fixed consecutive number schedules (FCN 8 and FCN 32).
Topics: Amphetamine; Animals; Chlordiazepoxide; Citalopram; Ethanol; Haloperidol; Imipramine; Impulsive Behavior; Learning; Male; Metergoline; Psychotropic Drugs; Rats; Rats, Sprague-Dawley | 1998 |
[Effects of serotonergic drugs on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum].
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Citalopram; Corpus Striatum; Dopamine Antagonists; Haloperidol; Male; Pyrazines; Rats; Rats, Wistar; Receptors, Dopamine D2; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Up-Regulation | 1998 |
Antidepressants and atypical neuroleptics induce Fos-like immunoreactivity in the central extended amygdala.
Topics: Amygdala; Animals; Antidepressive Agents; Antipsychotic Agents; Citalopram; Clozapine; Gene Expression Regulation; Genes, fos; Haloperidol; Imipramine; Male; Neurons; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 1999 |
The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Citalopram; Corpus Striatum; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Fluorobenzenes; Haloperidol; Indoles; Male; Microdialysis; Phenols; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 2000 |
Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.
Topics: Acoustic Stimulation; Adult; Citalopram; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituation, Psychophysiologic; Haloperidol; Humans; Ketanserin; Male; Models, Psychological; N-Methyl-3,4-methylenedioxyamphetamine; Psychiatric Status Rating Scales; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Serotonin | 2001 |
[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Topics: Adrenergic Uptake Inhibitors; Animals; Benzylamines; Brain; Carrier Proteins; Cats; Citalopram; Dopamine Antagonists; Fluoxetine; Haloperidol; Maprotiline; Membrane Glycoproteins; Membrane Transport Proteins; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tissue Distribution; Tomography, Emission-Computed; Tranylcypromine | 2003 |
Conditional involvement of striatal serotonin3 receptors in the control of in vivo dopamine outflow in the rat striatum.
Topics: Amphetamine; Analgesics, Opioid; Animals; Brain Chemistry; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Citalopram; Cocaine; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Electrochemistry; Haloperidol; Male; Microdialysis; Morphine; Ondansetron; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT3; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT3 Receptor Antagonists; Tropanes | 2003 |
Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsych
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Animals, Outbred Strains; Benzodiazepines; Cebus; Citalopram; Clozapine; Cognition; Dihydropyridines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Haloperidol; Haplorhini; Humans; Indoles; Male; Mice; Molecular Structure; Motor Activity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D4; Risperidone; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2007 |
A case of a patient with both chorea and restless legs syndrome.
Topics: Adult; Analgesics, Opioid; Anti-Dyskinesia Agents; Chorea; Citalopram; Drug Therapy, Combination; Haloperidol; Humans; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors; Tramadol | 2008 |
Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain; Carrier Proteins; Citalopram; Drug Therapy, Combination; Gene Expression; Haloperidol; Homer Scaffolding Proteins; Male; Neurons; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Synaptic Transmission | 2009 |
Self-injury behavior in an adolescent with Wilson's disease.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Haloperidol; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Self Mutilation; Self-Injurious Behavior | 2009 |
A report from the 4th biennial conference of the international society of bipolar disorder (March 17-20, 2010 - Sao Paulo, Brazil).
Topics: Bipolar Disorder; Brazil; Citalopram; Dopamine Antagonists; Haloperidol; Humans; Selective Serotonin Reuptake Inhibitors | 2010 |
Antidepressants elevate GDNF expression and release from C₆ glioma cells in a β-arrestin1-dependent, CREB interactive pathway.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Arrestins; beta-Arrestins; Brain Neoplasms; Cell Line, Tumor; Citalopram; Cyclic AMP Response Element-Binding Protein; Desipramine; Dose-Response Relationship, Drug; Glial Cell Line-Derived Neurotrophic Factor; Glioblastoma; Haloperidol; Imipramine; Neurotransmitter Uptake Inhibitors; Phosphorylation; Rats; RNA Interference; Selective Serotonin Reuptake Inhibitors; Signal Transduction; Transcription, Genetic; Transfection; Up-Regulation; Valproic Acid | 2011 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psychological; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Haloperidol; Male; Olanzapine; Polypharmacy; Random Allocation; Rats; Rats, Sprague-Dawley; Schizophrenia | 2012 |
Low proarrhythmic potential of citalopram and escitalopram in contrast to haloperidol in an experimental whole-heart model.
Topics: Action Potentials; Animals; Citalopram; Haloperidol; Heart; Rabbits; Tachycardia, Ventricular | 2016 |
Effects of acute dopaminergic and serotonergic manipulations in the ACI paradigm depend on the basal valence of cognitive judgement bias in rats.
Topics: Animals; Citalopram; Cognition; Cues; Discrimination, Psychological; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Haloperidol; Judgment; Levodopa; Male; Optimism; Pessimism; Psychological Tests; Punishment; Rats, Sprague-Dawley; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin | 2017 |
Inhibition effects of some antidepressant drugs on pentose phosphate pathway enzymes.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Erythrocytes; Glucosephosphate Dehydrogenase; Haloperidol; Humans; Mirtazapine; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase | 2019 |
Dispersive Liquid-Liquid Microextraction Based Preconcentration of Selected Pesticides and Escitalopram Oxalate, Haloperidol, and Olanzapine from Wastewater Samples Prior to Determination by GC-MS.
Topics: Citalopram; Gas Chromatography-Mass Spectrometry; Haloperidol; Humans; Limit of Detection; Liquid Phase Microextraction; Olanzapine; Pesticides; Wastewater; Water Pollutants, Chemical | 2021 |